In the presence of BRAF inhibitors and activated RAS, BRAF forms a heterodimer with CRAF, which triggers the activation of the MEK/ERK pathway at the origin of pathologies such as squamous cell carcinoma [73]. This evidence concerns the gene BRAF and squamous cell carcinoma.